Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Pavletic Website

Steven Z. Pavletic, M.D., M.S.

Selected Publications

1)  Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ.
Hand grip strength and 2 minute walk test in chronic GVHD assessment: An analysis from the Chronic GVHD Consortium.
Biol. Blood Marrow Transplant. 2013.
[Journal]
2)  Treister N, Chai X, Kurland B, Pavletic S, Weisdorf D, Pidala J, Palmer J, Martin P, Inamoto Y, Arora M, Flowers M, Jacobsohn D, Jagasia M, Arai S, Lee SJ, Cutler C.
Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.
Bone Marrow Transplant. 2013.
[Journal]
3)  Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis.
Biol. Blood Marrow Transplant. 19: 632-9, 2013.
[Journal]
4)  Pavletic SZ, Fowler DH.
Are we making progress in GVHD prophylaxis and treatment?.
Hematology Am Soc Hematol Educ Program. 2012: 251-64, 2012.
[Journal]
5)  Bowen JD, Kraft GH, Wundes A, Guan Q, Maravilla KR, Gooley TA, McSweeney PA, Pavletic SZ, Openshaw H, Storb R, Wener M, McLaughlin BA, Henstorf GR, Nash RA.
Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.
Bone Marrow Transplant. 47: 946-51, 2012.
[Journal]
6)  Atkins HL, Muraro PA, van Laar JM, Pavletic SZ.
Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time?.
Biol. Blood Marrow Transplant. 18: S177-83, 2012.
[Journal]
7)  Inamoto Y, Martin PJ, Chai X, Jagasia M, Palmer J, Pidala J, Cutler C, Pavletic SZ, Arora M, Jacobsohn D, Carpenter PA, Flowers ME, Khera N, Vogelsang GB, Weisdorf D, Storer BE, Lee SJ.
Clinical Benefit of Response in Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. [Epub ahead of print], 2012.
[Journal]
8)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
[Journal]
9)  Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME.
Correlation between NIH composite skin score, patient reported skin score and outcome: results from the Chronic GVHD Consortium.
Blood. [Epub ahead of print], 2012.
[Journal]
10)  Dietrich-Ntoukas T, Cursiefen C, Westekemper H, Eberwein P, Reinhard T, Bertz H, Nepp J, Lawitschka A, Heiligenhaus A, Seitz B, Messmer EM, Meyer-ter-Vehn T, Basara N, Greinix H, Datiles MB, Lee SJ, Pavletic SZ, Wolff D.
Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD.
Cornea. 31: 299-310, 2012.
[Journal]
11)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
[Journal]
12)  Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani BN, Aljurf MD, Cairo MS, Drobyski WR, George B, Hahn T, Khera N, Litzow MR, Loren AW, Saber W, Arora M, Urbano-Ispizua A, Cutler C, Flowers ME, Spellman SR.
HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies.
Biol. Blood Marrow Transplant. 18: 1302-8, 2012.
[Journal]
13)  Arora M, Pidala J, Cutler CS, Chai X, Kurland B, Jacobsohn DA, Pavletic SZ, Palmer J, Vogelsang G, Jagasia M, Schultz K, Lee SJ.
Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study.
Leukemia. 2012.
[Journal]
14)  Mays J, Fassil H, Edwards D, Pavletic S, Bassim C.
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.
Oral Dis. 2012.
[Journal]
15)  Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Taylor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, Pavletic SZ.
Oral chronic graft-vs.-host disease characterization using the NIH scale.
J. Dent. Res. 91: 45S-51S, 2012.
[Journal]
16)  Palmer JM, Lee SJ, Chai X, Storer BE, Flowers ME, Schultz KR, Inamoto Y, Cutler C, Pidala J, Arora M, Jacobsohn DA, Carpenter PA, Pavletic SZ, Martin PJ.
Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. [Epub ahead of print], 2012.
[Journal]
17)  Bassim CW, Ambatipudi KS, Mays JW, Edwards DA, Swatkoski S, Fassil H, Baird K, Gucek M, Melvin JE, Pavletic SZ.
Quantitative Salivary Proteomic Differences in Oral Chronic Graft-versus-Host Disease.
J Clin Immunol. [Epub ahead of print], 2012.
[Journal]
18)  Pavletic SZ.
Response as an end point in treatment trials for acute GVHD.
Bone Marrow Transplant. 47: 161-3, 2012.
[Journal]
19)  Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T.
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Blood. 119: 296-307, 2012.
[Journal]
20)  St John L, Gordon SM, Childs R, Marquesen M, Pavletic SZ, Wu TX, Cozzarelli T, Schroeder E, Saria MG, Fall-Dickson JM.
Topical thalidomide gel in oral chronic GVHD and role of in situ cytokine expression in monitoring biological activity.
Bone Marrow Transplant. 2012.
[Journal]
21)  Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA.
Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research.
Biol Blood Marrow Transplant. [Epub ahead of print], 2012.
[Journal]
22)  Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ.
Validation of measurement scales in ocular graft-versus-host disease.
Ophthalmology. 119: 487-93, 2012.
[Journal]
23)  Mitchell SA, Jacobsohn D, Thormann Powers KE, Carpenter PA, Flowers ME, Cowen EW, Schubert M, Turner ML, Lee SJ, Martin P, Bishop MR, Baird K, Bolaños-Meade J, Boyd K, Fall-Dickson JM, Gerber LH, Guadagnini JP, Imanguli M, Krumlauf MC, Lawley L, Li L, Reeve BB, Clayton JA, Vogelsang GB, Pavletic SZ.
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
Biol. Blood Marrow Transplant. 17: 1619-29, 2011.
[Journal]
24)  Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, Horowitz MM, Pavletic SZ.
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
Blood. 117: 6714-20, 2011.
[Journal]
25)  Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E.
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Biol. Blood Marrow Transplant. 17: 1-17, 2011.
[Journal]
26)  Greinix HT, Loddenkemper C, Pavletic SZ, Holler E, Socié G, Lawitschka A, Halter J, Wolff D.
Diagnosis and staging of chronic graft-versus-host disease in the clinical practice.
Biol. Blood Marrow Transplant. 17: 167-75, 2011.
[Journal]
27)  Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix H, Halter J, Pavletic SZ, Holler E, Wolff D.
Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.
Bone Marrow Transplant. 46: 1283-95, 2011.
[Journal]
28)  Arai S, Jagasia M, Storer B, Chai X, Pidala J, Cutler C, Arora M, Weisdorf DJ, Flowers ME, Martin PJ, Palmer J, Jacobsohn D, Pavletic SZ, Vogelsang GB, Lee SJ.
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
Blood. 118: 4242-9, 2011.
[Journal]
29)  Pavletic SZ.
HSCT for AID: entering prime time?.
Blood. 118: 1438-9, 2011.
[Journal]
30)  Martires KJ, Baird K, Citrin DE, Hakim FT, Pavletic SZ, Cowen EW.
Localization of sclerotic-type chronic graft-vs-host disease to sites of skin injury: potential insight into the mechanism of isomorphic and isotopic responses.
Arch Dermatol. 147: 1081-6, 2011.
[Journal]
31)  Tran SD, Redman RS, Barrett AJ, Pavletic SZ, Key S, Liu Y, Carpenter A, Nguyen HM, Sumita Y, Baum BJ, Pillemer SR, Mezey E.
Microchimerism in salivary glands after blood- and marrow-derived stem cell transplantation.
Biol. Blood Marrow Transplant. 17: 429-33, 2011.
[Journal]
32)  Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S.
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
Biol. Blood Marrow Transplant. 17: 443-54, 2011.
[Journal]
33)  Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M, Cahn JY, Cairo MS, Herzig RH, Isola LM, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman SR, Weisdorf DJ, Wingard JR, Horowitz MM, Pavletic SZ.
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.
Blood. 118: 4472-9, 2011.
[Journal]
34)  Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, Mitchell SA, Datiles M, Hakim FT, Pavletic SZ, Cowen EW.
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.
Blood. 118: 4250-7, 2011.
[Journal]
35)  Ge AX, Ryan ME, Giaccone G, Hughes MS, Pavletic SZ.
Acupuncture treatment for persistent hiccups in patients with cancer.
J Altern Complement Med. 16: 811-6, 2010.
[Journal]
36)  Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M.
Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
Biol. Blood Marrow Transplant. 16: 543-7, 2010.
[Journal]
37)  Salit RB, Bishop MR, Pavletic SZ.
Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?.
Curr Hematol Malig Rep. 5: 229-38, 2010.
[Journal]
38)  Chien JW, Duncan S, Williams KM, Pavletic SZ.
Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
Biol. Blood Marrow Transplant. 16: S106-14, 2010.
[Journal]
39)  Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H.
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Biol. Blood Marrow Transplant. 16: 1611-28, 2010.
[Journal]
40)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH.
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Cancer. 116: 852-62, 2010.
[Journal]
41)  Mitchell SA, Leidy NK, Mooney KH, Dudley WN, Beck SL, LaStayo PC, Cowen EW, Palit P, Comis LE, Krumlauf MC, Avila DN, Atlam N, Fowler DH, Pavletic SZ.
Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD).
Bone Marrow Transplant. 45: 762-9, 2010.
[Journal]
42)  Pulanic D, Cowen EW, Baird K, Bishop MR, Pavletic SZ.
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
Bone Marrow Transplant. 45: 1469-70, 2010.
[Journal]
43)  Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S.
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Biol. Blood Marrow Transplant. 16: 563-4, 2010.
[Journal]
44)  Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
Biol. Blood Marrow Transplant. 16: 871-90, 2010.
[Journal]
45)  Grauer O, Wolff D, Bertz H, Greinix H, Kühl JS, Lawitschka A, Lee SJ, Pavletic SZ, Holler E, Kleiter I.
Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.
Brain. 133: 2852-65, 2010.
[Journal]
46)  Fall-Dickson JM, Mitchell SA, Marden S, Ramsay ES, Guadagnini JP, Wu T, St John L, Pavletic SZ.
Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
Biol. Blood Marrow Transplant. 16: 948-56, 2010.
[Journal]
47)  Imanguli MM, Atkinson JC, Mitchell SA, Avila DN, Bishop RJ, Cowen EW, Datiles MB, Hakim FT, Kleiner DE, Krumlauf MC, Pavletic SZ.
Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.
Biol. Blood Marrow Transplant. 16: 1362-9, 2010.
[Journal]
48)  Harris BA, Berger AM, Mitchell SA, Steinberg SM, Baker KL, Handel DL, Bolle JL, Bush EG, Avila D, Pavletic SZ.
Spiritual well-being in long-term survivors with chronic graft-versus-host disease after hematopoietic stem cell transplantation.
J Support Oncol. 8: 119-25, 2010.
[Journal]
49)  Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C.
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
Blood. 114: 4494-502, 2009.
[Journal]
50)  Martin PJ, Pavletic SZ.
Biology and management of chronic graft-versus-host disease.
Cancer Treat. Res. 144: 277-98, 2009.
[Journal]
51)  Williams KM, Chien JW, Gladwin MT, Pavletic SZ.
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
JAMA. 302: 306-14, 2009.
[Journal]
52)  Clark J, Yao L, Pavletic SZ, Krumlauf M, Mitchell S, Turner ML, Cowen EW.
Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease.
Arch Dermatol. 145: 918-22, 2009.
[Journal]
53)  Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M.
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
Blood. 113: 3110-8, 2009.
[Journal]
54)  Pulanic D, Lozier JN, Pavletic SZ.
Thrombocytopenia and hemostatic disorders in chronic graft versus host disease.
Bone Marrow Transplant. 44: 393-403, 2009.
[Journal]
55)  Patel AR, Turner ML, Baird K, Gea-Banacloche J, Mitchell S, Pavletic SZ, Wise B, Cowen EW.
Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients.
Biol. Blood Marrow Transplant. 15: 370-6, 2009.
[Journal]
56)  Pavletic SZ, Fowler DH.
.
Blood. 111: 4838-9, 2008.
[Journal]
57)  Griffith LM, Pavletic SZ, Lee SJ, Martin PJ, Schultz KR, Vogelsang GB.
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.
Biol. Blood Marrow Transplant. 14: 379-84, 2008.
[Journal]
58)  Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH.
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
Ann. Oncol. 19: 1935-40, 2008.
[Journal]
59)  Imanguli MM, Alevizos I, Brown R, Pavletic SZ, Atkinson JC.
Oral graft-versus-host disease.
Oral Dis. 14: 396-412, 2008.
[Journal]
60)  Patel AR, Avila D, Malech HL, Pavletic SZ, Yao L, Cowen EW.
Rippled skin, fasciitis, and joint contractures.
J. Am. Acad. Dermatol. 59: 1070-4, 2008.
[Journal]
61)  Nikolov NP, Pavletic SZ.
Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease.
Nat Clin Pract Rheumatol. 4: 184-91, 2008.
[Journal]
62)  Patel AR, Pavletic SZ, Turner ML, Cowen EW.
The isomorphic response in morphealike chronic graft-vs-host disease.
Arch Dermatol. 144: 1229-31, 2008.
[Journal]
63)  Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett AJ, Bishop MR, Childs RW, Fowler DH, Pavletic SZ, Hart TC.
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
Exp. Hematol. 35: 184-92, 2007.
[Journal]
64)  Subramaniam DS, Fowler DH, Pavletic SZ.
Chronic graft-versus-host disease in the era of reduced-intensity conditioning.
Leukemia. 21: 853-9, 2007.
[Journal]
65)  Pavletic SZ, Zhou G, Sobocinski K, Marti G, Doney K, DiPersio J, Feremans W, Foroni L, Goodman S, Prentice G, LeMaistre C, Bandini G, Ferrant A, Jacobsen N, Khouri I, Gale RP, Wiestner A, Giralt S, Montserrat E, Chan WC, Bredeson C.
Genetically identical twin transplantation for chronic lymphocytic leukemia.
Leukemia. 21: 2452-5, 2007.
[Journal]
66)  Shlomchik WD, Lee SJ, Couriel D, Pavletic SZ.
Transplantation's greatest challenges: advances in chronic graft-versus-host disease.
Biol. Blood Marrow Transplant. 13: 2-10, 2007.
[Journal]
67)  Baird K, Pavletic SZ.
Chronic graft versus host disease.
Curr. Opin. Hematol. 13: 426-35, 2006.
[Journal]
68)  Pavletic SZ, Lee SJ, Socie G, Vogelsang G.
Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials.
Bone Marrow Transplant. 38: 645-51, 2006.
[Journal]
69)  Imanguli MM, Pavletic SZ, Guadagnini J, Brahim JS, Atkinson JC.
Chronic graft versus host disease of oral mucosa: review of available therapies.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 101: 175-83, 2006.
[Journal]
70)  Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB.
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.
Biol. Blood Marrow Transplant. 12: 31-47, 2006.
[Journal]
71)  Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB.
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.
Biol. Blood Marrow Transplant. 12: 252-66, 2006.
[Journal]
72)  Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR, Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic SZ, Lee SJ.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
Biol. Blood Marrow Transplant. 12: 491-505, 2006.
[Journal]
73)  Griffith LM, Pavletic SZ, Tyndall A, Gratwohl A, Furst DE, Forman SJ, Nash RA.
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapy.
Biol. Blood Marrow Transplant. 12: 688-90, 2006.
[Journal]
74)  Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA, Mittleman B, Vogelsang GB, Pavletic SZ.
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report.
Biol. Blood Marrow Transplant. 12: 126-37, 2006.
[Journal]
75)  Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL.
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Biol. Blood Marrow Transplant. 12: 22-30, 2006.
[Journal]
76)  Illei GG, Pavletic SZ.
Blood stem cells as therapy for severe lupus.
Expert Opin Biol Ther. 5: 1153-64, 2005.
[Journal]
77)  Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, Gratwohl A, van Laar JM, Mayes MD, Martin R, McSweeney PA, Muraro PA, Openshaw H, Saccardi R, Sandmaier BM, Forman SJ, Nash RA.
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005.
Biol. Blood Marrow Transplant. 11: 862-70, 2005.
[Journal]
78)  Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos E, Gingrich R, Casper J, Yanovich S, Weisdorf D.
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.
Blood. 106: 3308-13, 2005.
[Journal]
79)  Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A.
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Am. J. Hematol. 78: 265-74, 2005.
[Journal]
80)  Pavletic SZ, Illei GG.
The role of immune ablation and stem cell transplantation in severe SLE.
Best Pract Res Clin Rheumatol. 19: 839-58, 2005.
[Journal]
81)  Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
J. Clin. Oncol. 23: 5788-94, 2005.
[Journal]
82)  Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, Van Laar J, Verburg R, Szer J, Taylor K, Joske D, Rule S, Bingham SJ, Emery P, Burt RK, Lowenthal RM, Durez P, McKendry RJ, Pavletic SZ, Espigado I, Jantunen E, Kashyap A, Rabusin M, Brooks P, Bredeson C, Tyndall A.
Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
J. Rheumatol. 31: 482-8, 2004.
[Journal]
83)  Bredeson CN, Pavletic SZ.
Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease.
Best Pract Res Clin Haematol. 17: 327-43, 2004.
[Journal]
84)  Healey KM, Pavletic SZ, Al-Omaishi J, Leuschen MP, Pirruccello SJ, Filipi ML, Enke C, Ursick MM, Hahn F, Bowen JD, Nash RA.
Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation.
Mult. Scler. 10: 284-9, 2004.
[Journal]
85)  Aoun P, Blair HE, Smith LM, Dave BJ, Lynch J, Weisenburger DD, Pavletic SZ, Sanger WG.
Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
Leuk. Lymphoma. 45: 1595-603, 2004.
[Journal]
86)  Aoun P, Wiggins M, Pickering D, Foran J, Rasheed H, Pavletic SZ, Sanger W.
Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
Cancer Genet. Cytogenet. 154: 138-43, 2004.
[Journal]
87)  Pavletic SZ.
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease.
Arthritis Rheum. 50: 2387-90, 2004.
[Journal]
88)  Nola M, Pavletic SZ, Weisenburger DD, Smith LM, Bast MA, Vose JM, Armitage JO.
Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma.
Am. J. Hematol. 77: 31-5, 2004.
[Journal]
89)  Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, Fowler DH, Bishop MR, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs RW, Illei GG, Leitman SF, Malech HL, Horwitz ME.
Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells.
Blood. 103: 3986-8, 2004.
[Journal]
90)  Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH.
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
Br. J. Haematol. 126: 837-43, 2004.
[Journal]
91)  Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, Childs R, Barrett AJ, Csaky KG.
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.
Bone Marrow Transplant. 33: 1031-5, 2004.
[Journal]
92)  Van Laar JM, Pavletic SZ.
CD34-selected versus unmanipulated grafts for severe rheumatoid arthritis: comment on the article by Moore et al.
Arthritis Rheum. 48: 1463-4; author reply 1464-6, 2003.
[Journal]
93)  McGuire TR, Gwilt P, Manouvilov K, Healey K, Ursick MM, Nash RA, Pavletic SZ.
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Int. Immunopharmacol. 3: 279-83, 2003.
[Journal]
94)  Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH.
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
Blood. 102: 2364-72, 2003.
[Journal]
95)  Pavletic SZ, Bociek RG, Foran JM, Rubocki RJ, Kuszynski CA, Wisecarver JL, Hatcher L, Lucas DM, Byrd JC, Grever MR, Joshi SS, Hardiman P, Smith LM, McGuire TR, Bierman PJ, Vose JM, Armitage JO, Talmadge JE.
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.
Transplantation. 76: 877-81, 2003.
[Journal]
96)  Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB.
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.
Blood. 102: 802-9, 2003.
[Journal]
97)  Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR.
Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
Bone Marrow Transplant. 29: 709-10, 2002.
[Journal]
98)  Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A, Bishop MR.
Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics.
Blood. 98: 1963-70, 2001.
[Journal]
99)  Pavletic SZ, Odell JR, Pirruccello SJ, Ursick MM, Haire CE, Sharp JG, Kessinger A, Klassen LW.
Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: the University of Nebraska experience.
J Rheumatol Suppl. 64: 13-20, 2001.
[Journal]
100)  McGuire TR, Bociek GR, Pavletic SZ, Hock L, Lynch J, Schneider J, Hoie EB, Tarantolo S, Haire WD.
Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations.
Bone Marrow Transplant. 28: 889-93, 2001.
[Journal]
101)  Pavletic SZ, Klassen LW, Pope R, O'Dell JR, Traynor AE, Haire CE, Graziano F, Oyama Y, Barr W, Burt RK.
Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis.
J Rheumatol Suppl. 64: 28-31, 2001.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/18/2013.